Regadenoson API (CAS#313348-27-5)

Regadenoson is a pharmacologic stress agent used in nuclear cardiology procedures to assess the blood flow to the heart. It belongs to a class of drugs known as adenosine receptor agonists. This compound is specifically designed to mimic the effects of adenosine, a naturally occurring substance in the body that plays a crucial role in regulating blood flow and heart function.

Regadenoson acts by selectively binding to adenosine A₂A receptors on the smooth muscle cells of blood vessels in the heart. This binding triggers a series of biochemical events that lead to vasodilation, or widening of the blood vessels. By increasing blood flow to the heart, regadenoson allows for better visualization of the heart muscle during imaging procedures such as myocardial perfusion imaging (MPI).

The activation of adenosine A₂A receptors by regadenoson also has a positive chronotropic effect, meaning it increases the heart rate. This effect is an important part of the stress response induced by regadenoson, as it simulates the physiological changes that occur during exercise.

One of the primary applications of regadenoson is in nuclear cardiology for the diagnosis of coronary artery disease (CAD). CAD is a common condition characterized by the narrowing or blockage of the coronary arteries, which supply blood to the heart muscle. Nuclear cardiology procedures using regadenoson can help detect areas of reduced blood flow to the heart, indicating the presence of CAD.

During a regadenoson stress test, the patient is injected with a small amount of regadenoson, followed by an injection of a radioactive tracer. The tracer accumulates in the heart muscle in proportion to the blood flow. A special camera then takes images of the heart, allowing the doctor to assess the distribution of blood flow and identify areas of potential blockages.

Regadenoson stress tests are particularly useful for patients who are unable to exercise or who have physical limitations that prevent them from undergoing traditional exercise stress tests. They are also valuable for detecting CAD in patients with an intermediate risk of the disease.

In addition to its diagnostic applications, regadenoson also shows promise as a therapeutic agent. Research is ongoing to explore its potential use in the treatment of various cardiovascular conditions, such as heart failure and myocardial ischemia.

For example, in heart failure patients, regadenoson may help improve blood flow to the heart and enhance cardiac function. By dilating the blood vessels and increasing oxygen delivery to the heart muscle, it could potentially reduce symptoms and improve the quality of life for these patients.

In myocardial ischemia, regadenoson may be used to increase blood flow to the affected areas of the heart and prevent further damage. This could be achieved by administering regadenoson in combination with other drugs or therapeutic interventions.

Hot Tags: regadenoson api (cas#313348-27-5), China regadenoson api (cas#313348-27-5) manufacturers, suppliers, , medical raw materials CAS 56 75 7